Lancet · 2017

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I.

Show affiliations

El-Khoueiry AB — USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: elkhouei@med.usc.edu.
Sangro B — Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
Yau T — University of Hong Kong, Hong Kong Special Administrative Region, China.
Crocenzi TS — Providence Cancer Center, Portland, OR, USA.
Kudo M — Kindai University Faculty of Medicine, Osaka, Japan.
Hsu C — National Taiwan University Hospital, Taipei, Taiwan.
Kim TY — Seoul National University Hospital, Seoul, South Korea.
Choo SP — National Cancer Center, Singapore.
Trojan J — Goethe University Hospital and Cancer Center, Frankfurt, Germany.
Welling TH Rd — University of Michigan School of Medicine, Ann Arbor, MI, USA.
Meyer T — Royal Free Hospital, London, UK.
Kang YK — Asan Medical Center, University of Ulsan, Seoul, South Korea.
Yeo W — Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Chopra A — Johns Hopkins Singapore International Medical Centre, Singapore.
Anderson J — Bristol-Myers Squibb, Princeton, NJ, USA.
Dela Cruz C — Bristol-Myers Squibb, Princeton, NJ, USA.
Lang L — Bristol-Myers Squibb, Princeton, NJ, USA.
Neely J — Bristol-Myers Squibb, Princeton, NJ, USA.
Tang H — Bristol-Myers Squibb, Princeton, NJ, USA.
Dastani HB — Bristol-Myers Squibb, Princeton, NJ, USA.
Melero I — Biomedical Research Network in Oncology (CIBERONC), Pamplona, Spain; Center for Applied Medical Research (CIMA), Pamplona, Spain.